IRB #

STUDY00020075

Title

[NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Principal Investigator

Charles Lopez

Study Purpose

The purpose of this study is to find if adding the study drug, nivolumab after standard chemotherapy and radiation will prevent the anal cancer from returning

Medical Condition(s)

anal cancer

Eligibility Criteria

- Participants must have stage IIB, IIIA, IIIB, or IIIC squamous cell carcinoma of the anus of anorectum

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Participants will be on study for up to 5 years from the time of study entry through follow up.

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

ECOG-ACRIN

Recruitment End

06/01/2022

Compensation Provided

No


Go Back